Acurx Pharmaceuticals (ACRX) is a biopharmaceutical company focused on developing and commercializing new drugs for the treatment of gastrointestinal infections. Their main product is a novel type of antibiotic aimed at treating infections caused by C. difficile bacteria, known for their resistance to common antibiotics. Acurx Pharmaceuticals is committed to innovative research and development of drugs that can alleviate the burden associated with the treatment of gastrointestinal infections. Acurx Pharmaceuticals (ACRX) shares could be suitable for investors tracking new technologies in the field of gastrointestinal infection treatment and seeking opportunities to diversify their investment portfolio.
Feed
There are no posts to show right now.
Używamy ciasteczek, aby ulepszyć Twoje doświadczenie na naszej stronie.
